相似文献
1
Secondary osteoporosis.
Aust Prescr. 2016 Jun;39(3):85-7. doi: 10.18773/austprescr.2016.038. Epub 2016 Jun 1.
2
Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.
Calcif Tissue Int. 1997 Feb;60(2):148-54. doi: 10.1007/s002239900205.
3
The management of secondary osteoporosis.
Best Pract Res Clin Rheumatol. 2005 Dec;19(6):1021-37. doi: 10.1016/j.berh.2005.06.005.
4
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
Ann Intern Med. 2007 Mar 6;146(5):326-39. doi: 10.7326/0003-4819-146-5-200703060-00005.
5
Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture.
J Clin Endocrinol Metab. 2011 May;96(5):1360-7. doi: 10.1210/jc.2010-2135. Epub 2011 Mar 16.
6
Independent association of bone mineral density and trabecular bone score to vertebral fracture in male subjects with chronic obstructive pulmonary disease.
Osteoporos Int. 2018 Mar;29(3):615-623. doi: 10.1007/s00198-017-4314-7. Epub 2017 Nov 22.
7
Secondary screening for osteoporosis in patients admitted with minimal-trauma fracture to a major teaching hospital.
Intern Med J. 2003 Nov;33(11):505-10. doi: 10.1046/j.1445-5994.2003.00468.x.
8
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Nefrologia. 2008;28 Suppl 3:67-78.
9
Strategies for treatment to prevent fragility fractures in postmenopausal women.
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):727-40. doi: 10.1016/j.berh.2009.09.001.
10
Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture.
Eur J Endocrinol. 2013 Jul 15;169(2):225-37. doi: 10.1530/EJE-13-0102. Print 2013 Aug.
引用本文的文献
1
Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study.
BMC Nephrol. 2025 Apr 18;26(1):197. doi: 10.1186/s12882-025-04099-y.
2
Osteoporosis management in patients presenting to the emergency department with fragility fractures: A retrospective observational study.
J Diabetes Metab Disord. 2025 Feb 24;24(1):71. doi: 10.1007/s40200-025-01585-w. eCollection 2025 Jun.
3
AMPD1 and MTHFR genes are not associated with calcium levels in rheumatoid arthritis patients with methotrexate therapy in Indonesia.
Sci Rep. 2025 Jan 10;15(1):1647. doi: 10.1038/s41598-024-69604-z.
4
Sirt1: An Increasingly Interesting Molecule with a Potential Role in Bone Metabolism and Osteoporosis.
Biomolecules. 2024 Aug 8;14(8):970. doi: 10.3390/biom14080970.
5
Preoperative Thyroid-Stimulating Hormone Levels and Three-Year Mortality in Elderly Hip Fracture Patients: Insights from a Prospective Cohort Study.
Med Sci Monit. 2024 Aug 5;30:e944465. doi: 10.12659/MSM.944465.
6
Osteoporosis: Investigations and Monitoring.
Indian J Orthop. 2023 Dec 1;57(Suppl 1):70-81. doi: 10.1007/s43465-023-01019-w. eCollection 2023 Dec.
7
Methotrexate Increases Serum Calcium Levels in Patients with Rheumatoid Arthritis: A Retrospective Study at a Referral Hospital in Indonesia.
Curr Ther Res Clin Exp. 2023 Nov 12;99:100726. doi: 10.1016/j.curtheres.2023.100726. eCollection 2023.
8
Continuous positive airway pressure treatment improves bone mineral density in men affected by severe obstructive sleep apnea syndrome.
J Clin Sleep Med. 2024 Jan 1;20(1):67-73. doi: 10.5664/jcsm.10796.
9
A diagnostic predictive model for secondary osteoporosis in patients with fragility fracture: a retrospective cohort study in a tertiary care hospital.
Arch Osteoporos. 2023 Sep 6;18(1):114. doi: 10.1007/s11657-023-01321-y.
10
An overview of the management of osteoporosis in the aging female population.
Womens Health (Lond). 2023 Jan-Dec;19:17455057231176655. doi: 10.1177/17455057231176655.
本文引用的文献
1
Secondary osteoporosis - an endocrinological approach focusing on underlying mechanisms.
Endocr Regul. 2013 Jul;47(3):137-48. doi: 10.4149/endo_2013_03_137.
2
Osteoporosis in young adults: pathophysiology, diagnosis, and management.
Osteoporos Int. 2012 Dec;23(12):2735-48. doi: 10.1007/s00198-012-2030-x. Epub 2012 Jun 9.
3
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.
Ann Lab Med. 2012 Mar;32(2):105-12. doi: 10.3343/alm.2012.32.2.105. Epub 2012 Feb 23.
4
Laboratory testing for secondary osteoporosis evaluation.
Clin Biochem. 2012 Aug;45(12):894-900. doi: 10.1016/j.clinbiochem.2012.01.024. Epub 2012 Feb 4.
5
Approach to the patient with secondary osteoporosis.
Eur J Endocrinol. 2010 Jun;162(6):1009-20. doi: 10.1530/EJE-10-0015. Epub 2010 Mar 15.
6
Search for hidden secondary causes in postmenopausal women with osteoporosis.
Menopause. 2010 Jan-Feb;17(1):135-9. doi: 10.1097/gme.0b013e3181ade8e5.
7
Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years.
Clin Rheumatol. 2006 Feb;25(1):30-4. doi: 10.1007/s10067-005-1132-7. Epub 2005 May 25.
8
Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.
J Clin Endocrinol Metab. 2002 Oct;87(10):4431-7. doi: 10.1210/jc.2002-020275.
9
Secondary causes of osteoporosis.
Mayo Clin Proc. 2002 May;77(5):453-68. doi: 10.4065/77.5.453.
Zotero 插件